Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of ...

Akebia Therapeutics shares were down 20% to $2.27 after the company priced its underwritten public offering of 25 million shares at $2 a share. All shares are being offered by Akebia. The proceeds to ...

Roth Capital Partners and Clear Street LLC are acting as active joint book-running managers for the Offering. Rosenblatt Securities Inc. is acting as a passive book-running manager. The Benchmark ...

Shares of Akebia Therapeutics fell after the company said it has commenced an underwritten public offering. The stock sank 21% to $2.24 in after-hours trading Wednesday. Shares ended the regular ...

The Company filed an amended and restated preliminary short form prospectus (the " A&R Prospectus ”) on March 20, 2025 with ...

Cryptocurrency exchange Kraken is preparing to go public, capitalizing on improved regulatory conditions in the United States ...

According to Renaissance Capital, 2025 has been a "green light" year for initial public offerings, with 36 new U.S. IPOs priced so far this year. That's up 63.6% over the same period a year ago.

BOCA RATON, Fla.--(BUSINESS WIRE)--Newsmax Inc. (“Newsmax” or the “Company”) today announced the launch of its initial public offering (IPO) under Regulation A+, inviting investors ...

The company behind the Philippines’ top mobile wallet GCash is seeking a lower minimum public float of 10%-15% for its ...

The Philippine Stock Exchange Inc. (PSE), the operator of the country’s capital market, has allowed companies that will raise ...

The shares are being offered by Akebia pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on September 3, 2024 and declared effective by the ...